Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

A role for rituximab in depleting B cells and compromising their antigen ... Type II mixed essential CRYOGLOBULINEMIA (MEC) is often associated with hepatitis C virus (HCV) infection, and leads ...

Methods 125 patients with SLE treated with rituximab over 12 years were studied prospectively. A major clinical response was defined as improvement of all active British Isles Lupus Assessment Group ...

Anti-nuclear antibodies and anti-smooth muscle actin antibodies were negative. Tests for hepatitis B, hepatitis C virus, and HIV were also negative. The necessity of liver biopsy remains controversial ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus ... particularly B-cell depleting agents like rituximab, or disease. HBsAg-positivity also confers ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

As the number of immunosuppressive drugs has grown, so has the number of patients referred to gastroenterologists with hepatitis B reactivation, which can lead to acute liver failure. For patients ...